Bantwal: 23-year-old Muslim cleric feared drowned while crossing river

Karwar, Jun 3: The India Meteorological Department (IMD) has issued an alert, predicting thundershowers and heavy rainfall over north interior Karnataka, coastal Dakshina Kannada and Udupi over the next three days.

With Cyclone Nisarga hitting the Uttara Kannada coast on Tuesday,  parts of coastal Karnataka received heavy rainfall. Gusty winds tore through the coastal towns, as the sea too turned violent with rough waves smashing the shore.

The alert was issued with the advancement of Nisarga from east-central Arabian Sea to north Maharashtra, and adjoining south Gujarat coast. “Though it does not cover Karnataka, the range of cyclonic winds is very big and reaches north interior Karnataka also.

So an alert has been called out,” CS Patil, director in-charge, IMD, Bengaluru, said. The weather department has forecast a severe cyclonic storm and then a depression. Patil said formation of systems is a common factor before the onset of the monsoon and they help in its advancement.

“Cyclone Nisarga is helping in the quick advancement of the southwest monsoon to Karnataka, and the monsoon is likely to arrive before the scheduled date as conditions are favourable,” he added.

Bengaluru, May 13: Former chief minister and senior Congress leader Siddaramaiah on Wednesday called the measures announced by Finance Minister Nirmala Sitharaman as 'disastrous' and said it is 'non-existent' in terms of benefits to poor migrants, labourers, contract employees and farmers.

"The first set of measures announced by @FinMinIndia @nsitharaman, after 8 PM speech by @narendramodi, is disastrous & non-existent in terms of benefits to poor migrants, labourers, contract employees, farmers, etc," Siddaramaiah said in a tweet.

The Congress leader said most of the intended benefits may not reach the end recipient.

This comes a day after Prime Minister Narendra Modi announced a Rs 20 lakh crore special economic package to revive the COVID-19 hit economy.

"The contribution by the government for the schemes announced are mostly notional and less of actuals and the devil lies in the detail," the Congress leader said in another tweet.

After Sitharaman announced support measures for MSMEs, Siddaramaiah said, "The credit infusion to MSMEs may help them clear dues to vendors but it is doubtful if they shall utilise the credit available to pay their labourers & to prevent job cuts. @FinMinIndia should have taken measures to pay part of the salaries to the employees in MSMEs."

Further questioning the Centre on 'ignoring the spending for boosting consumption', Siddaramaiah said, "The government is interested in capital infusion in the form of credits but totally ignorant of the actual spending that needs to be done to boost consumption. How can credit be considered as government spending?"

Siddaramaiah said the next set of measures should benefit the marginalised sections.

"Will be looking forward to next set of measures & I hope it will be something to benefit the marginalised sections. Direct benefits to the poorest sections will help them survive this pandemic. COVID-19 fight should not be another perception battle but a real one," he added in another tweet.

Sitharaman earlier announced Rs 3 lakh crore collateral-free automatic loans for businesses, including MSMEs.

Besides this, she also stated that to provide stressed MSMEs with equity support, the government will facilitate the provision of Rs 20,000 crore as subordinate debt.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.